Illicit Cannabis Usage as a Management Strategy in New Zealand Women with Endometriosis: An Online Survey

Armour et al. ·Journal of Women's Health Impact 1.5

Klarer Nutzen GRADE Niedrig 46 Zitate

Stichproben = 484 Pat.

DauerMai bis Juli 2019

EndpunktSchmerzkontrolle

Verblindungn.a.

DesignKohortenstudie

Kernaussage

Cannabis wurde von 95,5% zur Schmerzlinderung und Schlafverbesserung verwendet; 81% berichteten, dass Schmerzen 'viel besser' wurden, und 81,4% reduzierten ihre regulären Medikamente.

Zusammenfassung

Duplikat: n=484 neuseeländische Frauen mit Endometriose, Online-Umfrage zu illegalem Cannabis-Konsum; 13% aktueller Gebrauch, 40% früherer Gebrauch zur Symptomkontrolle; selbstberichtete Wirksamkeit für Schmerzreduktion bei 77% der Nutzerinnen, aber keine objektive Messung oder Kontrollgruppe; deskriptive Querschnittsdaten.

PopulationFrauen mit selbst-berichteter Endometriose-Diagnose, n=213, mittleres Alter 32 Jahre, 79,8% aktive Cannabis-Nutzerinnen

InterventionIllicit Cannabis (verschiedene Applikationsformen), selbst-administriert zur Symptomkontrolle

Outcome95,5% nutzten Cannabis für Schmerzlinderung und Schlafverbesserung; 81% berichten 'viel bessere' Schmerzkontrolle, 81,4% reduzierten reguläre Medikation, 59% stoppten mindestens ein Medikament (66% Analgetika, 40% Opioide)

Vertrauen in die Evidenz

Niedrig

Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.

Qualitätsprofil

Größe ★★★★★

Verblindung —

Effektstärke Klarer Nutzen

Zitate / Jahr ★★★★★

Autoren

Armour M, Sinclair J, Noller G et al.

DOI 10.1089/jwh.2020.8668↗

Design: Kohortenstudie

Abstract

Background: Endometriosis affects around 10% of women worldwide. Many women with endometriosis struggle with finding adequate pain management, and data from other countries suggest that women use cannabis, either legal or illicit, to help manage their endometriosis symptoms. The aim of this study was to determine use of cannabis where endometriosis was self-identified as a condition that was being treated with cannabis, as well as the impact of cannabis use on the usage on other pharmaceuticals. Materials and Methods: A cross-sectional online survey of those using cannabis for health-related conditions run between May and July 2019. This article reports on the subset of this larger data set for those reporting they had a diagnosis of endometriosis and/or polycystic ovary syndrome. Data were collected on demographics, modes of cannabis administration, symptoms treated, changes in pharmaceutical usage, and adverse events. Results: Two hundred thirteen valid responses were analyzed. Mean age of respondents was 32 years and 79.8% were current cannabis users. The most common outcomes that cannabis was used for were to improve pain relief (95.5%) and to improve sleep (95.5%). Respondents reported that their symptom was "much better" for pain (81%), sleep (79%), and nausea or vomiting (61%). Over three-quarters (81.4%) indicated cannabis had reduced their normal medication usage. Over half (59%) were able to completely stop a medication, most commonly (66%) analgesics. Opioids (40%) were the most common class of analgesic stopped. Conclusions: Cannabis is reported as an effective intervention for pain and other endometriosis symptoms with potential substitution effects on opioid usage.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel